EDITORIAL article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1680969
This article is part of the Research TopicPARP inhibitors resistance: new insights in ovarian cancer therapyView all 5 articles
"Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapy"
Provisionally accepted
- 1National and Kapodistrian University of Athens, Athens, Greece
- 2Universite de Geneve, Geneva, Switzerland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In recent years, the therapeutic landscape of ovarian cancer has nevertheless undergone a dramatic shift with the implementation of targeted therapies, including the antiangiogenic monoclonal antibody bevacizumab and the orally administered poly (ADP-ribose) polymerase inhibitors (PARPi). By harnessing the principle of synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), especially those harboring BRCA1/2 genomic alterations, PARPi have provided meaningful clinical benefits. Of note, 25% of epithelial ovarian cancer cases are attributed to BRCA1/2 mutations, whereas almost 50% exhibit HRD.Yet, resistance emergence is rather inevitable leading to incurable disease recurrence and unfavorable prognosis. In light of this therapeutic challenge the Research Topic "PARP inhibitors resistance: new insights in ovarian cancer therapy" of Frontiers in Oncology comprises four insightful original articles that not only enhance our understanding of PARPi mechanism of action but also elucidate the complexity of the underlying resistance mechanisms, as well as explore emerging translational strategies in order to overcome these hurdles and improve patients' outcomes.In their comprehensive review, Kulkarni S. et al (1) Taken together, the aforementioned contributions provide a cohesive and future-oriented perspective on the biology and clinical translation of PARPi resistance. It has been our privilege to curate this Research Topic, which we sincerely hope will serve not only as a valuable scientific resource but also as a catalyst for future research, ultimately advancing the pursuit of personalized thus optimal treatment strategies for ovarian cancer patients.
Keywords: ovarian cancer, PARP inhibitors, resistance mechanisms, biomarkers, homologous recombination deficiency (HRD), BRCA 1/2 mutations
Received: 06 Aug 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Fiste, Liontos and Labidi-galy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Oraianthi Fiste, National and Kapodistrian University of Athens, Athens, Greece
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.